RHOA mutations encoding a Gly17Val alteration affecting GTPase activity and inhibiting the proposed tumor suppressor function of active RHOA was identified in 53-68% of AITL cases and was similarly identified to coexist with the presence of a TET2 mutation (47–49). This evidence concerns the gene RHOA and neoplasm.